Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 52-Week Low – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $78.50 and last traded at $79.38, with a volume of 1552 shares. The stock had previously closed at $83.90.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZLDPF shares. JPMorgan Chase & Co. initiated coverage on shares of Zealand Pharma A/S in a research report on Friday, November 8th. They set an “overweight” rating for the company. William Blair raised shares of Zealand Pharma A/S to a “hold” rating in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research report on Tuesday, January 21st.

Zealand Pharma A/S Stock Performance

The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The firm has a market capitalization of $5.64 billion, a PE ratio of -33.64 and a beta of 0.88. The firm has a fifty day moving average price of $100.67 and a 200 day moving average price of $111.95.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.19. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $28.11 million. Zealand Pharma A/S had a negative net margin of 1,725.03% and a negative return on equity of 15.24%. Research analysts anticipate that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.